Literature DB >> 28601297

Outcomes of multimodal management for sinonasal squamous cell carcinoma.

Arnaud Paré1, Pierre Blanchard2, Silvia Rosellini3, Anne Aupérin3, Philippe Gorphe4, Odile Casiraghi5, Stéphane Temam4, François Bidault6, Philippe Page7, Frédéric Kolb4, François Janot4, Antoine Moya Plana8.   

Abstract

BACKGROUND: Poor prognosis of sinonasal cancers (SNC) is usually due to the non-specific symptoms leading to late diagnosis with locally advanced disease. However, previous prognostic studies were often based on heterogeneous cohorts because of the scarcity of SNC. With squamous cell carcinoma being the main histological subgroup, the study aimed to perform a prognostic analysis on sinonasal squamous cell carcinoma (SNSCC) particularly, and to evaluate the oncological results of a multimodal therapy.
METHODS: A retrospective review of 68 cases involving SNSCC treatment between 1998 and 2012 at Gustave Roussy Cancer Campus was performed. Clinical, pathological, and treatment characteristics were evaluated as prognostic markers for oncological outcomes.
RESULTS: The 5-year overall survival (OS) and progression-free survival (PFS) rates were 58.1% and 52.6% respectively. Tumor downsizing under neoadjuvant chemotherapy (NACT) was observed in 82.5% of cases. The main pattern of recurrence was local with a 2- and 5-year rate of 37.3%. Decreased OS, PFS and local control were associated with involvement of the orbit, the soft tissue, and the suprastructure (p < 0.005).
CONCLUSION: Prognosis of surgically treated SNSCC remains poor. Multimodal treatment combining NACT followed by wide resection requiring complex reconstruction and adjuvant radiation therapy seems to provide promising results.
Copyright © 2017 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Free flaps; Neoadjuvant chemotherapy; Oncological failure; Sinonasal cancer; Squamous cell carcinoma

Mesh:

Year:  2017        PMID: 28601297     DOI: 10.1016/j.jcms.2017.05.006

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  7 in total

Review 1.  Multimodal Therapy for Sinonasal Malignancies: Updates and Review of Current Treatment.

Authors:  Mayur D Mody; Nabil F Saba
Journal:  Curr Treat Options Oncol       Date:  2020-01-16

2.  Outcomes in surgical management of sinonasal malignancy-A single comprehensive cancer center experience.

Authors:  Dauren Adilbay; Cristina Valero; Conall Fitzgerald; Avery Yuan; Ximena Mimica; Piyush Gupta; Richard J Wong; Jatin P Shah; Snehal G Patel; Ian Ganly; Marc A Cohen
Journal:  Head Neck       Date:  2022-01-25       Impact factor: 3.147

3.  Prognostic Analysis of HPV Status in Sinonasal Squamous Cell Carcinoma.

Authors:  Alexandre Tendron; Marion Classe; Odile Casiraghi; Hélène Pere; Caroline Even; Philippe Gorphe; Antoine Moya-Plana
Journal:  Cancers (Basel)       Date:  2022-04-08       Impact factor: 6.575

4.  Outcomes of Management of Sinonasal Malignancies at a Dedicated Cancer Institution: A Retrospective Study.

Authors:  Rahim Dhanani; Muhammad Faisal; Hamza Shahid; Kashif Iqbal Malik; Arif Jamshed; Raza Hussain
Journal:  Ann Maxillofac Surg       Date:  2021-07-24

5.  Prognostic Nomograms for Predicting Overall Survival and Cancer-Specific Survival in Patients with Head and Neck Mucosal Melanoma.

Authors:  Zhenzhang Lu; Yuxiang Zhou; Guohui Nie; Beiping Miao; Yongtian Lu; Tao Chen
Journal:  Int J Gen Med       Date:  2022-03-10

6.  Prognostic Impact of Adverse Pathologic Features in Sinonasal Squamous Cell Carcinoma.

Authors:  Anuraag S Parikh; Jennifer C Fuller; Ashton E Lehmann; Neerav Goyal; Stacey T Gray; Derrick T Lin
Journal:  J Neurol Surg B Skull Base       Date:  2020-05-19

7.  Down-regulating NEAT1 inhibited the viability and vasculogenic mimicry formation of sinonasal squamous cell carcinoma cells via miR-195-5p/VEGFA axis.

Authors:  Honglue Lu; Fei Kang
Journal:  Biosci Rep       Date:  2020-11-27       Impact factor: 3.840

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.